MRK - Why Is Cancer Therapy Focused Evaxion Biotech Stock Trading Higher Today? | Benzinga
Evaxion Biotech A/S (NASDAQ:EVAX) announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens named Endogenous Retroviruses (ERVs).
ERVs are remnants of ancient viruses lying dormant in a human genome. ERVs are often overexpressed in cancer but not in healthy tissue, making them visible to the immune system and hence promising targets for cancer vaccines.
AI-Immunology is crucial in identifying therapeutically relevant ERV tumor antigens from genomic patient tumor data.
Evaxion says the new treatment opportunity may broaden the applicability of cancer vaccines, and treating ...